You are here: Industry Insights > Breast Cancer

News List

NICE recommends Eli Lilly’s breast cancer drug Verzenios pharmatimes
August 13, 2021
Draft NICE guidance has recommended Eli Lilly’s twice-daily pill Verzenios (abemaciclib) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.
Enhertu improves progression-free survival in breast cancer trial pharmatimes
August 09, 2021
Positive topline results from a Phase III trial for Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu have shown that the HER2-directed antibody drug conjugate (ADC) ADC demonstrated superiority over trastuzumab emtansine (T-DM1).
Arvinas and Pfizer enter up to $2.4bn deal to develop breast cancer drug pharmaceutical-technology
July 26, 2021
Arvinas and Pfizer have entered an international partnership to jointly develop and market the former’s investigational therapy, ARV-471, for breast cancer.
Gap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by Enough drugs
July 05, 2021
Racial disparities in breast cancer survival have narrowed in recent years, but Black women with the disease still have double the death rate of white women.
Women's Cancer Screenings Plummeted During Pandemic drugs
July 01, 2021
Breast and cervical cancer screenings dropped sharply among low-income minority women during the COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention says.
Researchers identify new drug class with potential in BRCA-mutated tumours pharmatimes
June 21, 2021
Researchers from the The Institute of Cancer Research, London and Artios have identified a new class of drugs – POLQ inhibitors – which could have potential for patients with BRCA-mutated tumours.
Israeli scientists find promising target for breast cancer and other cancer therapeutics expresspharma
June 21, 2021
Ben-Gurion University of the Negev and National Institute for Biotechnology in the Negev (NIBN) scientist Prof Dan Levy has discovered a novel mechanism that is a promising target for cancer therapeutics.
Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors prnasia
June 15, 2021
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the Investigational New Drug (IND) application for the ...
Sanofi partners with BIG, EORTC, AFT to study amcenestrant for ER+ breast cancer treatment expresspharma
June 07, 2021
Amcenestrant is an oral SERD that antagonises and degrades the estrogen receptor (ER), resulting in inhibition of the ER signaling pathway.
Lynparza shows promise in preventing cancer recurrence pharmatimes
June 04, 2021
AstraZeneca and MSD's Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page